ArticleFrontiers in oncology2020

CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model.

Suet Ling Felce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.